CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Agios Pharmaceuticals, Inc.

AGIO
$2.05BMid Cap

Next catalyst

Phase 2March 2027

AG-120

Chondrosarcoma

Get an email about AGIO's next catalysts

Track Agios Pharmaceuticals (AGIO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

2 upcoming, 1 past

PDUFA
⏸Delayed

FDA PDUFA Date mitapivat (sickle cell disease)

Feb 1, 2027Mitapivat

For Sickle cell disease. sNDA, accelerated approval, Priority Review. Verified against the company announcement on 2026-10-16.

Date changed: 2026-11-01 → 2027-02-01. New PDUFA goal date of February 1, 2027 for the mitapivat sNDA in sickle cell disease; company states it is launch-ready and in labeling discussions with FDA.

Source
Phase 2Next

AG-120 Phase 2 Est. Readout

March 2027~AG-1206

Estimated primary completion for AG-120 trial (NCT04278781) in Chondrosarcoma. Topline data typically follows completion by weeks to months.

Source

How AGIO's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE536 employees

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 1

Website
Drug Pipeline

Frequently asked questions

What is in Agios Pharmaceuticals, Inc.'s drug pipeline?→

CatalystAlert tracks 6 drug candidates in Agios Pharmaceuticals, Inc.'s (AGIO) pipeline across Phase 3, Phase 2. Its lead program is Mitapivat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Agios Pharmaceuticals, Inc.'s next FDA catalyst?→

Agios Pharmaceuticals, Inc.'s (AGIO) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track AGIO biotech catalysts?→

Add AGIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Agios Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply